A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms

Lori K. Mattison, Martin R. Johnson, Robert B Diasio

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

A pharmacogenetic syndrome caused by molecular defects in the dihydropyrimidine dehydrogenase gene (DPYD) results in partial to complete loss of dihydropyrimidine dehydrogenase (DPD) enzyme activity with patients exhibiting life-threatening toxicity following administration of routine doses of 5-fluorouracil. To date, more than 19 reported mutations have been putatively associated with DPD deficiency with 16 occurring within the open reading frame of the cDNA. The purpose of this study was to examine the conservation of functional domains (including the uracil, flavine adenine dinucleotide and NADPH binding sites) across three phyla (Chordata, Arthropoda and Nematoda) and the conservation of regions corresponding to the previously reported mutations. Comparative analysis of the uracil and NADPH binding sites in mammals and invertebrates demonstrated 100% amino acid identity between mammals and Drosophila melanogaster. Caenorhabditis elegans demonstrated 89% and 88% identity in these domains, respectively. The mammalian sequences demonstrated 100% identity in two iron sulphur motifs (amino acids 953-964 and 986-997) with significant conservation in D. melanogaster (92% and 92% identity, respectively) and C. elegans (100% and 92% identity, respectively). Comparative amino acid analysis revealed non-conservation in the loci of four DPYD mutations [DPYD* 12 (R21Q), DPYD* 5 (1543V), DPYD* 6 (V7321), DPYD* 9A (C29R)]. Seven mutations occurred in highly conserved regions [M166V, DPYD* 8 (R235W), DPYD* 11 (V3351), DPYD* 4 (S534N), DPYD* 9B (R886H), D949V, DPYD* 10 (V995F)]. In summary, this comparative analysis identified conserved regions which may be critical to enzyme structure and/or function. The conservation of loci where DPYD mutations occur was also examined to evaluate their functional significance on DPD enzyme activity. These data should prove useful in the evaluation of newly discovered mutations in the DPYD gene.

Original languageEnglish (US)
Pages (from-to)133-144
Number of pages12
JournalPharmacogenetics
Volume12
Issue number2
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Dihydrouracil Dehydrogenase (NADP)
Genetic Polymorphisms
Complementary DNA
Genes
Mutation
Uracil
Caenorhabditis elegans
Drosophila melanogaster
NADP
Mammals
Dihydropyrimidine Dehydrogenase Deficiency
Enzymes
Binding Sites
Chordata
Sulfur Amino Acids
Amino Acids
Nematoda
Arthropods
Pharmacogenetics

Keywords

  • 5-fluorouracil
  • Dihydropyrimidine dehydrogenase
  • Dihydropyrimidine dehydrogenase deficiency
  • Pharmacogenetic
  • Pharmacogenomic
  • Species comparison

ASJC Scopus subject areas

  • Genetics
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms. / Mattison, Lori K.; Johnson, Martin R.; Diasio, Robert B.

In: Pharmacogenetics, Vol. 12, No. 2, 2002, p. 133-144.

Research output: Contribution to journalArticle

@article{34cda9133fbc4e819e8eabfed3596049,
title = "A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms",
abstract = "A pharmacogenetic syndrome caused by molecular defects in the dihydropyrimidine dehydrogenase gene (DPYD) results in partial to complete loss of dihydropyrimidine dehydrogenase (DPD) enzyme activity with patients exhibiting life-threatening toxicity following administration of routine doses of 5-fluorouracil. To date, more than 19 reported mutations have been putatively associated with DPD deficiency with 16 occurring within the open reading frame of the cDNA. The purpose of this study was to examine the conservation of functional domains (including the uracil, flavine adenine dinucleotide and NADPH binding sites) across three phyla (Chordata, Arthropoda and Nematoda) and the conservation of regions corresponding to the previously reported mutations. Comparative analysis of the uracil and NADPH binding sites in mammals and invertebrates demonstrated 100{\%} amino acid identity between mammals and Drosophila melanogaster. Caenorhabditis elegans demonstrated 89{\%} and 88{\%} identity in these domains, respectively. The mammalian sequences demonstrated 100{\%} identity in two iron sulphur motifs (amino acids 953-964 and 986-997) with significant conservation in D. melanogaster (92{\%} and 92{\%} identity, respectively) and C. elegans (100{\%} and 92{\%} identity, respectively). Comparative amino acid analysis revealed non-conservation in the loci of four DPYD mutations [DPYD* 12 (R21Q), DPYD* 5 (1543V), DPYD* 6 (V7321), DPYD* 9A (C29R)]. Seven mutations occurred in highly conserved regions [M166V, DPYD* 8 (R235W), DPYD* 11 (V3351), DPYD* 4 (S534N), DPYD* 9B (R886H), D949V, DPYD* 10 (V995F)]. In summary, this comparative analysis identified conserved regions which may be critical to enzyme structure and/or function. The conservation of loci where DPYD mutations occur was also examined to evaluate their functional significance on DPD enzyme activity. These data should prove useful in the evaluation of newly discovered mutations in the DPYD gene.",
keywords = "5-fluorouracil, Dihydropyrimidine dehydrogenase, Dihydropyrimidine dehydrogenase deficiency, Pharmacogenetic, Pharmacogenomic, Species comparison",
author = "Mattison, {Lori K.} and Johnson, {Martin R.} and Diasio, {Robert B}",
year = "2002",
doi = "10.1097/00008571-200203000-00007",
language = "English (US)",
volume = "12",
pages = "133--144",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms

AU - Mattison, Lori K.

AU - Johnson, Martin R.

AU - Diasio, Robert B

PY - 2002

Y1 - 2002

N2 - A pharmacogenetic syndrome caused by molecular defects in the dihydropyrimidine dehydrogenase gene (DPYD) results in partial to complete loss of dihydropyrimidine dehydrogenase (DPD) enzyme activity with patients exhibiting life-threatening toxicity following administration of routine doses of 5-fluorouracil. To date, more than 19 reported mutations have been putatively associated with DPD deficiency with 16 occurring within the open reading frame of the cDNA. The purpose of this study was to examine the conservation of functional domains (including the uracil, flavine adenine dinucleotide and NADPH binding sites) across three phyla (Chordata, Arthropoda and Nematoda) and the conservation of regions corresponding to the previously reported mutations. Comparative analysis of the uracil and NADPH binding sites in mammals and invertebrates demonstrated 100% amino acid identity between mammals and Drosophila melanogaster. Caenorhabditis elegans demonstrated 89% and 88% identity in these domains, respectively. The mammalian sequences demonstrated 100% identity in two iron sulphur motifs (amino acids 953-964 and 986-997) with significant conservation in D. melanogaster (92% and 92% identity, respectively) and C. elegans (100% and 92% identity, respectively). Comparative amino acid analysis revealed non-conservation in the loci of four DPYD mutations [DPYD* 12 (R21Q), DPYD* 5 (1543V), DPYD* 6 (V7321), DPYD* 9A (C29R)]. Seven mutations occurred in highly conserved regions [M166V, DPYD* 8 (R235W), DPYD* 11 (V3351), DPYD* 4 (S534N), DPYD* 9B (R886H), D949V, DPYD* 10 (V995F)]. In summary, this comparative analysis identified conserved regions which may be critical to enzyme structure and/or function. The conservation of loci where DPYD mutations occur was also examined to evaluate their functional significance on DPD enzyme activity. These data should prove useful in the evaluation of newly discovered mutations in the DPYD gene.

AB - A pharmacogenetic syndrome caused by molecular defects in the dihydropyrimidine dehydrogenase gene (DPYD) results in partial to complete loss of dihydropyrimidine dehydrogenase (DPD) enzyme activity with patients exhibiting life-threatening toxicity following administration of routine doses of 5-fluorouracil. To date, more than 19 reported mutations have been putatively associated with DPD deficiency with 16 occurring within the open reading frame of the cDNA. The purpose of this study was to examine the conservation of functional domains (including the uracil, flavine adenine dinucleotide and NADPH binding sites) across three phyla (Chordata, Arthropoda and Nematoda) and the conservation of regions corresponding to the previously reported mutations. Comparative analysis of the uracil and NADPH binding sites in mammals and invertebrates demonstrated 100% amino acid identity between mammals and Drosophila melanogaster. Caenorhabditis elegans demonstrated 89% and 88% identity in these domains, respectively. The mammalian sequences demonstrated 100% identity in two iron sulphur motifs (amino acids 953-964 and 986-997) with significant conservation in D. melanogaster (92% and 92% identity, respectively) and C. elegans (100% and 92% identity, respectively). Comparative amino acid analysis revealed non-conservation in the loci of four DPYD mutations [DPYD* 12 (R21Q), DPYD* 5 (1543V), DPYD* 6 (V7321), DPYD* 9A (C29R)]. Seven mutations occurred in highly conserved regions [M166V, DPYD* 8 (R235W), DPYD* 11 (V3351), DPYD* 4 (S534N), DPYD* 9B (R886H), D949V, DPYD* 10 (V995F)]. In summary, this comparative analysis identified conserved regions which may be critical to enzyme structure and/or function. The conservation of loci where DPYD mutations occur was also examined to evaluate their functional significance on DPD enzyme activity. These data should prove useful in the evaluation of newly discovered mutations in the DPYD gene.

KW - 5-fluorouracil

KW - Dihydropyrimidine dehydrogenase

KW - Dihydropyrimidine dehydrogenase deficiency

KW - Pharmacogenetic

KW - Pharmacogenomic

KW - Species comparison

UR - http://www.scopus.com/inward/record.url?scp=0036219855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036219855&partnerID=8YFLogxK

U2 - 10.1097/00008571-200203000-00007

DO - 10.1097/00008571-200203000-00007

M3 - Article

C2 - 11875367

AN - SCOPUS:0036219855

VL - 12

SP - 133

EP - 144

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 2

ER -